Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
789.00
Value Traded
0.24
Short % Float
-
Days to Cover
1.9
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
BPTH Catalyst Timeline
Dated clinical, regulatory and corporate events for Bio-Path Holdings Inc
Past FDA Catalysts and PDUFA Decisions
How BPTH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | BP1001-A | IND Submission | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every BPTH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| prexigebersen | AML | Phase 2 | 2025-06-03 | two patients who have demonstrated continued treatment durability; over 15 treatment cycles; complete remission; median survival of only 5 to 10 monthsRead More | Bio-Path Holdings Provides Clinical and Operational UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sherwood AlineDirector | Grant/Award | 10,000 10,000 held | $0.00 | 03/31/2022 |
Hedge Fund 13F Activity
Hedge Funds invested in BPTH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in BPTH for Q2 2026. | ||||
Ownership Trends
BPTH Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
2.4K
Shares Sold Short
0.0% vs prior count
1.9 Low
Days to Cover
trading days of normal volume to buy every short share back
1.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BPTH ranks across every disease it competes in
Competitive Position is a premium feature
See how BPTH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBPTH News
-BPTH
Jun 9, 2025Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum
HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced Pete
Read more →-BPTH
Jun 3, 2025Bio-Path Holdings Provides Clinical and Operational Update
Bio-Path Holdings provided a clinical and operational update highlighting progress in its drug development pipeline. The company is conducting Phase 2 trials for prexigebersen in AML and Phase 1/1b trials for BP1001-A and BP1002 in solid tumors and relapsed/refractory AML, respectively. Positive patient responses have been noted, and the company plans to file an IND for BP1003 in 2025.
Read more →-BPTH
May 22, 2025Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it w
Read more →-BPTH
May 1, 2025▲ +11%on this news
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
HOUSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today reported the
Read more →-BPTH
Mar 28, 2025▼ -8.7%on this news
Bio-Path Holdings Reports Full Year 2024 Financial Results
HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its fi
Read more →-BPTH
Mar 18, 2025▼ -8.7%on this news
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
HOUSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today reported re
Read more →-BPTH
Feb 13, 2025Bio-Path Holdings Expands Global Patent Portfolio
Bio-Path Holdings has announced the issuance of new patents in the U.S. and New Zealand, enhancing its global intellectual property portfolio. The patents cover technologies aimed at treating cancer and obesity, particularly focusing on STAT3 inhibition. The CEO highlighted the importance of these patents in safeguarding the company's innovations and advancing clinical programs. Bio-Path currently holds a total of 68 patents globally, with ongoing efforts to expand its portfolio further.
Read more →-BPTH
Feb 13, 2025▼ -12.5%on this news· ran to -82% by day 3shared move
Bio-Path Holdings Provides Key Clinical Updates
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase 2 Triple Combination Study of Prexigebersen in Acute Myeloid Leukemia (AML) HO
Read more →-BPTH
Feb 12, 2025▼ -12.5%on this news· ran to -82% by day 3shared move
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
Bio-Path Holdings has provided an update on its Phase 1/1b clinical trial of BP1002 for refractory/relapsed acute myeloid leukemia (AML). The trial has advanced to the fourth dose cohort of 90 mg/m2, with one patient showing a significant response after one treatment cycle. The study aims to address the urgent need for effective treatments for venetoclax-resistant AML patients, who typically have a median survival of less than three months.
Read more →-BPTH
Jan 10, 2025Bio-Path Holdings Provides 2025 Clinical and Operational Update
Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary
Read more →-BPTH
Dec 19, 2024▲ +122.7%on this news
Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today reported that results f
Read more →-BPTH
Dec 11, 2024Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic Program and Discontinues Enrollment in Phase 1 Study of BP1002 to Treat Relapsed/Refractory Lymphoma and Relapsed/R
Read more →-BPTH
Nov 15, 2024▼ -9.7%on this news
Bio-Path Holdings Reports Third Quarter 2024 Financial Results
Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanopartic
Read more →-BPTH
Nov 8, 2024Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host
Read more →-BPTH
Oct 10, 2024Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs,
Read more →-BPTH
Oct 9, 2024▼ -7.6%on this newsshared move
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs,
Read more →-BPTH
Oct 8, 2024▲ +39.8%on this newsshared move
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
HOUSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the initiatio
Read more →-BPTH
Sep 16, 2024Bio-Path Holdings Announces Publication in Biomedicines
Manuscript Highlights Therapeutic Potential of BP1003 in Variety of Cancers Marks Company’s Twenty-Second Peer-Reviewed Publication in Support of its DNAbilize® Technology HOUSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology compan
Read more →-BPTH
Sep 3, 2024Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
HOUSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter N
Read more →-BPTH
Aug 21, 2024Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease Reports Continued Patient Progress from Phase 2 Triple Combination Study of Prexigebersen in Acute Myeloid Leukemia (AML) Su
Read more →About Bio-Path Holdings Inc
BIOPHARMAWATCH ELITE
Trade the next BPTH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime